<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4.</segment>
<segment id="2" parent="1002" relname="preparation">Treatments for Diabetic Foot Ulcers</segment>
<segment id="3" parent="1002" relname="joint">One strategy for the management of patients with a DFU is to introduce a multidisciplinary approach</segment>
<segment id="4" parent="1004" relname="span">and address the multifactorial processes</segment>
<segment id="5" parent="4" relname="elaboration">involved in DFUs .</segment>
<segment id="6" parent="1008" relname="span">The use of multi-disciplinary teams</segment>
<segment id="7" parent="6" relname="restatement">( MDTs )</segment>
<segment id="8" parent="1009" relname="span">that include all relevant specialties</segment>
<segment id="9" parent="8" relname="elaboration">( i.e. , nursing , orthopedics , plastic surgery , vascular surgery , nutrition , and endocrinology departments )</segment>
<segment id="10" parent="1011" relname="span">has shown an effect</segment>
<segment id="11" parent="10" relname="elaboration">of decreasing the risks</segment>
<segment id="12" parent="1012" relname="joint">associated with DFUs and amputation by 50 – 85 % ,</segment>
<segment id="13" parent="1013" relname="joint">lowering costs ,</segment>
<segment id="14" parent="1013" relname="joint">and leading to a better quality of life for patients with DFUs .</segment>
<segment id="15" parent="1015" relname="span">Management of DFUs requires the correct classification of stage and severity .</segment>
<segment id="16" parent="15" relname="elaboration">Adequate care for DFUs should include a focus on DM control as well as on wound care , proper infection control , relieving pressure , and optimizing blood flow .</segment>
<segment id="17" parent="1002" relname="joint">The basic care for the control and treatment of DFUs is focused on the management of adequate perfusion , pressure mitigation , control of infection , and debridement .</segment>
<segment id="18" parent="1018" relname="span">With technological advancement , other series of therapies for DFUs have been implemented ,</segment>
<segment id="19" parent="1020" relname="span">such as the development of skin substitutes , negative pressure wound therapy , hyperbaric oxygen , the creation of new wound dressings</segment>
<segment id="20" parent="19" relname="elaboration">that include growth factors ,</segment>
<segment id="21" parent="1019" relname="same_unit">and the use of tissues from bioengineering .</segment>
<segment id="22" parent="1021" relname="joint">In this way , treatments for DPN , PAD , and infections have provided encouraging results .</segment>
<segment id="23" parent="1023" relname="preparation">4.1. Treatments for Diabetic Peripheral Neuropathy</segment>
<segment id="24" parent="1025" relname="span">DPN is a factor</segment>
<segment id="25" parent="24" relname="elaboration">that increases the risk of the appearance of a DFU ,</segment>
<segment id="26" parent="1026" relname="span">owing to the loss of sensation in the limb ,</segment>
<segment id="27" parent="26" relname="result">making patients vulnerable to trauma .</segment>
<segment id="28" parent="1023" relname="joint">Tight glycemic control is the primary step and a main feature of DPN management .</segment>
<segment id="29" parent="1023" relname="joint">Normoglycemia is more effectively restored by a pancreas transplant .</segment>
<segment id="30" parent="1031" relname="span">Several studies have demonstrated improvement of motor and sensory neuropathy in patients with DPN</segment>
<segment id="31" parent="30" relname="circumstance">after they were treated with a pancreas transplant .</segment>
<segment id="32" parent="1030" relname="contrast">However , discrepancies exist in the time of response .</segment>
<segment id="33" parent="1033" relname="span">Pharmacological treatment is used for painful DPN</segment>
<segment id="34" parent="33" relname="elaboration">manifested as numbness , burning , stabbing , or excruciating or intractable pain ;</segment>
<segment id="35" parent="1035" relname="span">only three treatments are approved by the U.S. Food and Drug Administration for the pain</segment>
<segment id="36" parent="35" relname="elaboration">associated with DPN ,</segment>
<segment id="37" parent="1023" relname="joint">namely , pregabalin , tapentadol , and duloxetine .</segment>
<segment id="38" parent="1038" relname="span">Another pharmacological therapy includes analgesics , such as tramadol , acetaminophen , and some opioids such as oxycodone ,</segment>
<segment id="39" parent="1039" relname="joint">which have constipation and nausea as side effects ,</segment>
<segment id="40" parent="1040" relname="span">and must be taken with care</segment>
<segment id="41" parent="40" relname="cause">because they can be misused .</segment>
<segment id="42" parent="1023" relname="joint">Therapy with antidepressants such as amitriptyline , nortriptyline , and venlafaxine , among others , has shown an efficacy in neuropathic pain management .</segment>
<segment id="43" parent="1023" relname="joint">It has an effect on the recapture of noradrenaline and serotonin , as well as on muscarinic effects .</segment>
<segment id="44" parent="1023" relname="joint">In spite of this ,</segment>
<segment id="45" parent="1045" relname="span">there are limited studies</segment>
<segment id="46" parent="1046" relname="span">evaluating these drugs</segment>
<segment id="47" parent="46" relname="cause">because their doses in clinical trials are not entirely reproducible in clinical practice .</segment>
<segment id="48" parent="1050" relname="span">Alpha-lipoic acid</segment>
<segment id="49" parent="48" relname="elaboration">( ALA )</segment>
<segment id="50" parent="1049" relname="same_unit">has been suggested as a potential therapeutic agent</segment>
<segment id="51" parent="1051" relname="joint">in treating DPN ;</segment>
<segment id="52" parent="1051" relname="joint">its antioxidant capacity seems to delay or reverse damages to peripheral nerves .</segment>
<segment id="53" parent="1054" relname="span">Several human randomized controlled trials</segment>
<segment id="54" parent="53" relname="restatement">( RCTs )</segment>
<segment id="55" parent="1053" relname="same_unit">have investigated the effects of ALA in the development of diabetic nephropathy .</segment>
<segment id="56" parent="1058" relname="span">A meta-analysis of four RCTs</segment>
<segment id="57" parent="56" relname="restatement">( n = 653 )</segment>
<segment id="58" parent="1057" relname="same_unit">showed</segment>
<segment id="59" parent="1061" relname="span">that , compared with placebo , intravenous ALA</segment>
<segment id="60" parent="59" relname="restatement">( 600 mg per day )</segment>
<segment id="61" parent="1060" relname="same_unit">decreased symptoms of neuropathy</segment>
<segment id="62" parent="1062" relname="contrast">when administered for three weeks ,</segment>
<segment id="63" parent="1064" relname="span">but symptom improvement with oral ALA</segment>
<segment id="64" parent="63" relname="elaboration">( &gt;600 mg per day for 3 – 5 weeks )</segment>
<segment id="65" parent="1063" relname="same_unit">was not clinically significant .</segment>
<segment id="66" parent="1067" relname="span">There is no evidence</segment>
<segment id="67" parent="66" relname="elaboration">evaluating long-term treatment .</segment>
<segment id="68" parent="1068" relname="span">Currently , treatments</segment>
<segment id="69" parent="1070" relname="span">based on the use of mesenchymal stem cells</segment>
<segment id="70" parent="69" relname="restatement">( MSC )</segment>
<segment id="71" parent="1070" relname="elaboration">derived from adipose tissue have been considered as a potential treatment against DPN .</segment>
<segment id="72" parent="1072" relname="span">These therapies promote the production of pro-angiogenic , neuroprotective , and anti-inflammatory factors ,</segment>
<segment id="73" parent="72" relname="elaboration">which have a positive impact on the clinical manifestations of the disease .</segment>
<segment id="74" parent="1074" relname="span">On the other hand , the use of biological therapy with low doses of IL-6 has been demonstrated</segment>
<segment id="75" parent="74" relname="purpose">to promote improvement of blood flow ,</segment>
<segment id="76" parent="1076" relname="sequence">decrease chronic inflammation ,</segment>
<segment id="77" parent="1076" relname="sequence">and regenerate peripheral nerve fibers .</segment>
<segment id="78" parent="1023" relname="joint">Accordingly , IL-6 may prove to be an effective treatment for the protection and/or restoration of peripheral nerve function in DPN ;</segment>
<segment id="79" parent="1079" relname="joint">see Table 1 .</segment>
<segment id="80" parent="1080" relname="span">4.2. Treatments for Peripheral Arterial Disease</segment>
<segment id="81" parent="80" relname="restatement">( Ischemia )</segment>
<segment id="82" parent="1081" relname="joint">Ischemia</segment>
<segment id="83" parent="1083" relname="span">presenting in diabetic patients due to a reduction in blood flow</segment>
<segment id="84" parent="1084" relname="span">that occurs in both small vessels</segment>
<segment id="85" parent="84" relname="elaboration">( microvascular , such as capillaries )</segment>
<segment id="86" parent="1086" relname="span">and large vessels</segment>
<segment id="87" parent="86" relname="elaboration">( macrovascular , such as arteries and veins ) ,</segment>
<segment id="88" parent="1087" relname="span">or due to a decrease of angiogenesis , can be treated through revascularization of at least one of the foot arteries</segment>
<segment id="89" parent="1090" relname="span">to try to restore blood flow in patients with a DFU</segment>
<segment id="90" parent="89" relname="elaboration">whose toe pressure is &lt;30 mmHg or transcutaneous oxygen pressure</segment>
<segment id="91" parent="1091" relname="span">( TcPO2 ) &lt;25 mmHg , as well as in those</segment>
<segment id="92" parent="1092" relname="span">who have a DFU</segment>
<segment id="93" parent="92" relname="elaboration">that does not heal with pressure on the ankle of &lt;50 mmHg or ankle-brachial index</segment>
<segment id="94" parent="1089" relname="elaboration">( ABI ) &lt;0.5 .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1004" type="span" parent="1002" relname="joint"/>
<group id="1006" type="multinuc" parent="1002" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="span" parent="1008" relname="elaboration"/>
<group id="1010" type="span" parent="1006" relname="same_unit"/>
<group id="1011" type="span" parent="1010" relname="span"/>
<group id="1012" type="multinuc" parent="1011" relname="elaboration"/>
<group id="1013" type="multinuc" parent="1012" relname="joint"/>
<group id="1015" type="span" parent="1002" relname="joint"/>
<group id="1017" type="multinuc" parent="1002" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="sequence"/>
<group id="1019" type="multinuc" parent="18" relname="elaboration"/>
<group id="1020" type="span" parent="1019" relname="same_unit"/>
<group id="1021" type="multinuc" parent="1017" relname="sequence"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="multinuc" parent="1022" relname="span"/>
<group id="1024" type="multinuc" parent="1023" relname="joint"/>
<group id="1025" type="span" parent="1024" relname="same_unit"/>
<group id="1026" type="span" parent="1024" relname="same_unit"/>
<group id="1030" type="multinuc" parent="1023" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="contrast"/>
<group id="1033" type="span" parent="1023" relname="joint"/>
<group id="1035" type="span" parent="1023" relname="joint"/>
<group id="1038" type="span" parent="1023" relname="joint"/>
<group id="1039" type="multinuc" parent="38" relname="elaboration"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1045" type="span" parent="1023" relname="joint"/>
<group id="1046" type="span" parent="45" relname="elaboration"/>
<group id="1048" type="span" parent="1023" relname="joint"/>
<group id="1049" type="multinuc" parent="1048" relname="span"/>
<group id="1050" type="span" parent="1049" relname="same_unit"/>
<group id="1051" type="multinuc" parent="1049" relname="circumstance"/>
<group id="1053" type="multinuc" parent="1023" relname="joint"/>
<group id="1054" type="span" parent="1053" relname="same_unit"/>
<group id="1056" type="span" parent="1023" relname="joint"/>
<group id="1057" type="multinuc" parent="1059" relname="attribution"/>
<group id="1058" type="span" parent="1057" relname="same_unit"/>
<group id="1059" type="span" parent="1056" relname="span"/>
<group id="1060" type="multinuc" parent="1059" relname="span"/>
<group id="1061" type="span" parent="1060" relname="same_unit"/>
<group id="1062" type="multinuc" parent="1060" relname="circumstance"/>
<group id="1063" type="multinuc" parent="1062" relname="contrast"/>
<group id="1064" type="span" parent="1063" relname="same_unit"/>
<group id="1067" type="span" parent="1023" relname="joint"/>
<group id="1068" type="span" parent="1023" relname="joint"/>
<group id="1069" type="span" parent="68" relname="elaboration"/>
<group id="1070" type="span" parent="1069" relname="span"/>
<group id="1072" type="span" parent="1023" relname="joint"/>
<group id="1074" type="span" parent="1023" relname="joint"/>
<group id="1076" type="multinuc" parent="1023" relname="joint"/>
<group id="1078" type="span" parent="1023" relname="joint"/>
<group id="1079" type="multinuc" parent="1081" relname="preparation"/>
<group id="1080" type="span" parent="1079" relname="joint"/>
<group id="1081" type="multinuc" parent="1078" relname="span"/>
<group id="1083" type="span" parent="1081" relname="joint"/>
<group id="1084" type="span" parent="83" relname="elaboration"/>
<group id="1085" type="multinuc" parent="1081" relname="joint"/>
<group id="1086" type="span" parent="1085" relname="contrast"/>
<group id="1087" type="span" parent="1085" relname="contrast"/>
<group id="1088" type="span" parent="88" relname="purpose"/>
<group id="1089" type="span" parent="1088" relname="span"/>
<group id="1090" type="span" parent="1089" relname="span"/>
<group id="1091" type="span" parent="1090" relname="elaboration"/>
<group id="1092" type="span" parent="91" relname="elaboration"/>
	</body>
</rst>
